Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

The investment seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). The fund is an actively ...

Concern about that link, particularly relating to teenage boys and young men, has been a key argument against administering ...

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

C&EN networking event in New York City. Please join us if you’re in town! Here’s a link to the invitation. Questions? Comments? Tips? Let us know. Email Michael McCoy, C&EN’s executive editor for ...

NVIDIA continues to fuel the AI stock rally in 2024. Our analysis shows that may be the case for the foreseeable future.

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Flu vaccines that take a page from the COVID-19 vaccine platform are making progress in clinical trials. In a phase 3 trial, Pfizer’s mRNA flu vaccine outperformed a traditional vaccine, researchers ...

About eight years ago, Grant decided he would never vaccinate his dogs again. A former Army medic, the Santa Barbara, ...